Document is current
Any future updates will be listed below
-
Authors
Rauh, Ulrike https://orcid.org/0000-0001-9120-9632
Wei, Guo
Serrano-Wu, Michael
Kosmidis, Georgios
Kaulfuss, Stefan
Siegel, Franziska
Thede, Kai
McFarland, James
Lemke, Christopher T. https://orcid.org/0000-0001-9419-1511
Werbeck, Nicolas
Nowak-Reppel, Katrin
Pilari, Sabine https://orcid.org/0009-0006-0668-293X
Menz, Stephan
Ocker, Matthias https://orcid.org/0000-0001-8263-6288
Zhang, Weiqun
Davis, Kyle
Poncet-Montange, Guillaume
Roth, Jennifer https://orcid.org/0000-0002-5117-5586
Daniels, Douglas https://orcid.org/0000-0003-0238-9403
Kaushik, Virendar K.
Hubbard, Brian
Ziegelbauer, Karl
Golub, Todd R. https://orcid.org/0000-0003-0113-2403
-
Funding
Funding for this research was provided by:
Broad Institute
Anji Onco Inc
Bayer
- License Information
-
More Information
Article History
Received: 31 January 2023
Accepted: 26 July 2024
First Online: 23 August 2024
Competing interests
: F.S. and S.M. are employees of Bayer AG. N.W., K.T., K.Z., S.K. and U.R. have been employees at Bayer AG, which funded the project. U.R. is an employee of Trueline Therapeutics, Inc. G.K. and S.P. have performed fee-for-service research work for Trueline Therapeutics, Inc. K.T., U.R., K.N-R. and K.Z. hold Bayer AG shares. J.M. has received research support through the Dependency Map Consortium. M.S.-W., D.D., M.O., V.K.K. and B.H. are employees of Anji Pharmaceuticals, Inc. K.Z. and T.R.G. are paid advisors on the scientific advisory board of Trueline Therapeutics, Inc. C.T.L. and T.R.G. have a financial stake in BRD-810. T.R.G. holds equity in Anji Pharmaceuticals, Inc. and is a paid advisor and/or equity holder in Dewpoint Therapeutics, Sherlock Biosciences, Amplifyer Bio and Braidwell, Inc. U.R., M.S.-W., K.T., C.T.L., N.W., S.K. and K.N.-R. are listed as inventors on published patent WO 2019096922-BRH-01825 covering BRD-810. The other authors declare no competing interests.
